Robert W. McMahon, SVP and Chief Financial Officer of West Pharmaceutical Services Inc, filed a Form 4 on August 12, 2026, disclosing restricted stock unit vesting and related share withholding transactions dated August 11, 2026.

Key Highlights

  • Two RSU tranches vested: 6,354.736 restricted stock units and 794.469 restricted stock units converted to common stock on August 11, 2026, each at $0 exercise price.
  • Shares withheld for taxes: 2,763.675 shares were disposed of at $351.37 per share in connection with the larger RSU vesting, and 345.515 shares were disposed of at $351.37 per share in connection with the smaller RSU vesting.
  • Resulting direct ownership: Following all reported transactions, McMahon directly held 7,020.506 shares of common stock.
  • Remaining RSU balance: After the vesting events, McMahon held 2,118.579 restricted stock units from the first award and 2,383.4 restricted stock units from the second award.
  • Grant history: The larger RSU tranche traces to a grant of 12,670 restricted stock units made on August 11, 2025, vesting in three installments over six, twelve, and twenty-four months from the grant date.
  • Filing signed by agent: The form was signed by Caitlin Hippeli as agent for Robert W. McMahon on August 12, 2026.

McMahon RSU Vesting Details: West Pharmaceutical Services CFO Transactions

According to the filing, Robert W. McMahon, identified as SVP and Chief Financial Officer of West Pharmaceutical Services Inc (NYSE:WST), reported two transaction code "M" events on August 11, 2026, reflecting the conversion of restricted stock units into common stock. The first conversion involved 794.469 restricted stock units, and the second involved 6,354.736 restricted stock units. The filing states that each restricted stock unit represents a contingent right to receive one share of WST common stock.

Concurrent with each vesting event, shares were withheld under transaction code "F" to satisfy tax obligations. The filing discloses that 345.515 shares were disposed of at $351.37 per share following the smaller vesting, and 2,763.675 shares were disposed of at $351.37 per share following the larger vesting. After both sets of transactions, the filing reports McMahon's direct beneficial ownership at 7,020.506 shares of common stock.

The filing explains that the larger RSU award originated from a grant of 12,670 restricted stock units on August 11, 2025, structured to vest in three installments: 4,223 shares (plus dividend equivalents) at six months, 6,335 shares (plus dividend equivalents) at twelve months, and 2,112 shares (plus dividend equivalents) at twenty-four months from the grant date. The smaller RSU award, according to the filing, vests in four equal annual installments beginning on August 11, 2026. Following the reported transactions, McMahon retained 2,118.579 units under the first award and 2,383.4 units under the second award.

What Was Disclosed

The filing discloses RSU-to-common-stock conversions and associated share withholdings for West Pharmaceutical Services CFO Robert W. McMahon on August 11, 2026, with resulting direct ownership of 7,020.506 shares and remaining RSU balances of 2,118.579 and 2,383.4 units respectively.